Aktis Oncology (NASDAQ:AKTS) Now Covered by Analysts at JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. began coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a note issued to investors on Tuesday. The brokerage set an “overweight” rating and a $30.00 price target on the technology company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 36.49% from the stock’s current price.

AKTS has been the subject of a number of other research reports. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Bank of America assumed coverage on Aktis Oncology in a research note on Tuesday. They set a “buy” rating and a $34.00 price objective for the company. TD Cowen began coverage on shares of Aktis Oncology in a report on Tuesday. They issued a “buy” rating for the company. Finally, Leerink Partners assumed coverage on shares of Aktis Oncology in a report on Tuesday. They set an “outperform” rating and a $31.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.67.

Aktis Oncology Stock Performance

AKTS opened at $21.98 on Tuesday. Aktis Oncology has a 1 year low of $18.52 and a 1 year high of $29.16.

Insider Activity

In other news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the purchase, the insider owned 5,671,825 shares in the company, valued at $102,092,850. The trade was a 17.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares in the company, valued at approximately $184,681,152. The trade was a 12.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 6,117,776 shares of company stock worth $110,119,968. Company insiders own 3.30% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.